Vitamin B12 Forms Compared: Cyanocobalamin vs Methylcobalamin vs Adenosylcobalamin

This content is for educational purposes only and is not a substitute for personalised nutrition advice from a qualified dietitian or healthcare professional.

Vitamin B12 is one of the most frequently discussed nutrients in integrative nutrition circles, yet the conversation rarely moves beyond "vegans need it." The form of B12 in a supplement matters considerably — different cobalamin forms have distinct metabolic roles, tissue distributions, and clinical applications. For individuals with MTHFR variants, neurological symptoms, chronic fatigue, or specific absorption challenges, choosing the wrong form can mean supplementing for years with minimal functional benefit.

Why B12 Form Matters: The Cobalamin Family

All forms of vitamin B12 share a corrin ring structure with a central cobalt atom. What differs is the ligand attached to that cobalt — and that ligand determines which enzymatic pathways the molecule can directly support, how it is transported, and how readily it crosses into specific tissues.

The four cobalamin forms in clinical and supplemental use are:

• Cyanocobalamin — the synthetic, stable form used in most mass-market supplements
• Methylcobalamin — the active methyl-donor form; the predominant form in blood and the brain
• Adenosylcobalamin (also called dibencozide) — the mitochondrial form; active in energy metabolism
• Hydroxocobalamin — a natural form used predominantly in injectable preparations

Each serves distinct biochemical roles. Understanding those roles is the foundation for choosing the right form.

Cyanocobalamin: Cheap, Stable, and Contested

Cyanocobalamin is the form found in the vast majority of multivitamins and B12 supplements because it is inexpensive to manufacture and highly shelf-stable. It is not a naturally occurring form in human metabolism — it is a synthetic compound in which a cyanide group occupies the cobalt ligand position.

Before it can be used by the body, cyanocobalamin must be converted to an active form. This conversion requires two steps: first to hydroxocobalamin (or aquocobalamin), then to either methylcobalamin or adenosylcobalamin depending on the enzymatic pathway. This conversion is generally efficient in healthy individuals with intact reductase enzymes.

The cyanide content is frequently raised as a concern. At standard supplemental doses (1–25 µg), the cyanide released is trivial and well within safe limits — the body's detoxification pathways handle it easily. At pharmacological doses (1,000 µg or more, used in clinical B12 deficiency treatment), the cumulative cyanide load is still well below toxic thresholds in people with normal renal function. However, cyanocobalamin is generally avoided in individuals with impaired cyanide clearance — such as heavy smokers or those with renal insufficiency — and hydroxocobalamin is preferred in these cases.

The more clinically relevant concern with cyanocobalamin is its dependency on complete conversion pathways. For individuals with genetic variants — particularly MTHFR and MTRR (methionine synthase reductase) polymorphisms — the enzymatic efficiency of this conversion may be reduced, making active forms a more reliable supplementation strategy.

Methylcobalamin: The Active Methyl Donor

Methylcobalamin is the form of B12 active in the cytoplasm and, critically, in the central nervous system. It donates its methyl group to homocysteine via the methionine synthase reaction, converting homocysteine to methionine. This reaction is the junction at which B12 intersects with the folate cycle — without adequate methylcobalamin, both homocysteine accumulates and the folate cycle becomes "trapped," impairing DNA synthesis.

Several properties make methylcobalamin clinically significant beyond simply being an active B12 form:

Blood-brain barrier penetration. Methylcobalamin crosses the blood-brain barrier more effectively than cyanocobalamin. Studies comparing cerebrospinal fluid B12 levels following supplementation with different forms have found higher CNS concentrations with methylcobalamin. This is particularly relevant for neurological applications.

MTHFR and methylation. Individuals carrying MTHFR C677T or A1298C variants have reduced capacity to convert folate to its active methylated form (5-MTHF). The downstream consequences include elevated homocysteine, impaired methionine regeneration, and disrupted methylation reactions throughout the body. For these individuals, providing pre-methylated B12 as methylcobalamin bypasses some of the enzymatic burden. The role of B12 in the methylation cycle extends well beyond preventing deficiency anaemia — it is about maintaining optimal flux through reactions that affect gene expression, neurotransmitter production, and detoxification.

Neurological conditions. Clinical evidence supports methylcobalamin supplementation specifically for peripheral neuropathy, with several Japanese clinical trials showing benefit for diabetic neuropathy and age-related sensory decline at doses of 1,500 µg per day. The neurological preference for methylcobalamin likely reflects both its superior blood-brain barrier penetration and its direct role in maintaining myelin integrity.

Homocysteine as a functional marker. Monitoring homocysteine and B12 status together provides a more complete picture than serum B12 alone. Elevated homocysteine in the presence of low-normal B12 strongly suggests functional deficiency even when serum B12 sits technically above the laboratory reference range.

Adenosylcobalamin: The Mitochondrial Form

Adenosylcobalamin (AdoCbl) is the form of B12 active inside mitochondria, where it serves as a cofactor for methylmalonyl-CoA mutase (MCM). This enzyme is essential for converting methylmalonyl-CoA to succinyl-CoA, a step in the catabolism of odd-chain fatty acids, branched-chain amino acids, and the amino acids methionine, threonine, and isoleucine. Succinyl-CoA then enters the citric acid cycle, feeding directly into ATP production.

When adenosylcobalamin is deficient, methylmalonyl-CoA accumulates and spills into the urine as methylmalonic acid (MMA). Elevated urinary or serum MMA is therefore a more sensitive early marker of functional B12 deficiency than low serum B12 alone — it specifically reflects inadequate adenosylcobalamin activity at the mitochondrial level.

For fatigue syndromes and energy metabolism complaints, adenosylcobalamin is arguably the more targeted form. Its role in mitochondrial substrate flow makes it directly relevant to ATP production efficiency. Some integrative practitioners combine methylcobalamin and adenosylcobalamin — the so-called "active B12 combination" — to address both the cytoplasmic methylation and mitochondrial energy functions simultaneously.

Adenosylcobalamin is less stable than methylcobalamin in light and at room temperature, which is why it is less commonly seen as a standalone supplement. It is typically found in formulations packaged in dark amber containers and may specify refrigeration. Its connection to cellular energy cofactors is relevant here — adenosylcobalamin's role in the citric acid cycle intersects with NAD+ metabolism, meaning that optimising mitochondrial B12 status may amplify the benefits of broader energy metabolism support.

Hydroxocobalamin: The Injectable Standard

Hydroxocobalamin is a naturally occurring form of B12 found in food, though in smaller amounts than methylcobalamin. It is not widely used as an oral supplement but is the standard form for intramuscular injection in the UK National Health Service and many European countries. Its key advantages include:

• Long half-life. Hydroxocobalamin binds more tightly to plasma proteins than cyanocobalamin, resulting in slower renal clearance and sustained serum levels. A monthly injection maintains therapeutic levels more consistently.
• No cyanide group. Hydroxocobalamin is preferred in patients where cyanide accumulation is a concern — heavy smokers, chronic renal failure — and at high doses it is the antidote for cyanide poisoning.
• Conversion flexibility. The body can convert hydroxocobalamin to either methylcobalamin or adenosylcobalamin as needed, making it a versatile precursor for both active forms.

For patients with pernicious anaemia (autoimmune destruction of intrinsic factor), atrophic gastritis, or post-gastrectomy states where oral absorption is categorically impaired, intramuscular hydroxocobalamin remains the gold standard treatment.

Sublingual vs Oral vs Injectable: What the Evidence Shows

Oral B12 absorption depends heavily on intrinsic factor (IF), a glycoprotein produced by gastric parietal cells. IF binds B12 in the stomach and carries it to the ileum, where the IF-B12 complex is absorbed via specific receptors. This system has a saturable capacity of approximately 1.5–2 µg per dose.

At very high oral doses (500–1,000 µg), approximately 1% is absorbed by passive diffusion independent of intrinsic factor. This is why high-dose oral cyanocobalamin is used therapeutically even in pernicious anaemia — the passive diffusion route, though inefficient, can deliver sufficient B12 at large enough doses. Clinical trials from Sweden and the UK have confirmed that high-dose oral B12 is as effective as intramuscular injection for maintaining serum levels in pernicious anaemia, provided patients take the tablets consistently.

Sublingual B12 — tablets dissolved under the tongue — is widely marketed as superior to oral for absorption. The evidence is mixed. Some studies show modestly higher bioavailability via the sublingual mucosa; others show no significant difference from equivalent oral doses. Sublingual is a reasonable practical choice for individuals who prefer to avoid injections, but it is not dramatically superior in most people with functioning intrinsic factor.

Intramuscular injection remains the most reliable route for individuals with confirmed absorption defects — pernicious anaemia, surgical loss of the terminal ileum, severe atrophic gastritis. It bypasses intestinal absorption entirely and achieves consistent, predictable serum levels regardless of gut status.

Optimal B12 Levels: Beyond the Reference Range

Standard laboratory reference ranges for serum B12 typically set the lower limit at 180–200 pmol/L (approximately 250–270 pg/mL). These thresholds were largely derived from populations with overt B12 deficiency anaemia, and they are poorly calibrated for detecting functional deficiency that produces neurological and cognitive symptoms before haematological changes appear.

Emerging evidence — including research correlating B12 levels with methylmalonic acid, homocysteine, and neuropsychiatric outcomes — suggests that functional B12 sufficiency is better reflected by levels of 400–900 pmol/L:

• Below 200 pmol/L: frank deficiency; treatment clearly indicated
• 200–400 pmol/L: grey zone; functional deficiency possible, particularly if MMA or homocysteine are elevated
• 400–900 pmol/L: target range associated with optimal neurological and metabolic function
• Above 900 pmol/L: high-normal; generally safe with supplementation, though very high levels warrant investigation for liver disease or myeloproliferative disorders if not explained by recent high-dose supplementation

In Australia, B12 testing is available via Medicare-funded pathways when clinically indicated. Patients with neurological symptoms, fatigue, or mood disorders should request a full panel — serum B12 plus MMA and homocysteine — rather than accepting serum B12 alone as a sufficient functional assessment.

Who Needs What: A Practical Decision Framework

Vegans and vegetarians: Any form of oral or sublingual B12 at adequate doses prevents deficiency. A minimum of 250 µg daily (to account for variable intrinsic factor saturation) or 2,000 µg weekly is the standard recommendation. Cyanocobalamin works well here because conversion efficiency is generally intact and it is the most studied form for this application. Methylcobalamin is an equally valid choice.

MTHFR variants (C677T or A1298C): Methylcobalamin is the preferred form. Providing pre-methylated B12 reduces dependence on conversion pathways that may be partially compromised. The combination of methylcobalamin and 5-MTHF (active folate) is the standard integrative approach for supporting methylation in this population.

Neurological symptoms — peripheral neuropathy, cognitive decline, depression, memory impairment: Methylcobalamin at higher doses (1,500 µg daily), given its superior CNS penetration and direct role in myelin maintenance. Some practitioners add adenosylcobalamin for a broader active B12 combination targeting both methylation and mitochondrial function.

Fatigue and poor energy production: Adenosylcobalamin, alone or combined with methylcobalamin. If fatigue is the primary complaint and serum B12 is low-normal, trialling an active B12 combination for 8–12 weeks is a reasonable evidence-informed strategy before pursuing more complex investigation.

Pernicious anaemia or confirmed absorption failure: Intramuscular hydroxocobalamin, or high-dose oral or sublingual B12 (1,000 µg daily) for those who decline injection, with regular monitoring of serum B12 and MMA to confirm adequacy.

Renal insufficiency or heavy smokers: Hydroxocobalamin preferred; avoid cyanocobalamin due to cyanide clearance concerns.

When selecting among supplement forms more broadly, the same analytical framework — examining the molecular form, conversion requirements, and clinical evidence — is the approach described in supplement form selection principles.

B12 and the Vegan Timeline to Deficiency

B12 is stored primarily in the liver, with total body stores of approximately 2–5 mg in healthy adults. Daily losses through bile and urine are small — around 1–3 µg per day. This means that even after completely eliminating dietary B12, it can take two to five years for stores to deplete to levels that produce symptoms, sometimes longer.

This delayed onset is both reassuring and deceptive. Many new vegans feel well for years while stores slowly deplete, then develop symptoms — often neurological — that are attributed to other causes before B12 deficiency is identified. By this point, neurological damage may be partially irreversible if deficiency has been prolonged.

The practical implication is clear: B12 supplementation should begin immediately upon adopting a vegan or near-vegan diet, not after symptoms appear. The timeline to deficiency varies by individual based on pre-existing stores and dietary history, but the risk of delayed-onset neurological damage makes waiting for symptoms a clinically unjustifiable approach.

Testing in Australia

Relevant B12-related tests and their clinical applications:

• Serum vitamin B12 — first-line assessment; interpret against the 400–900 pmol/L functional target rather than the lower reference limit alone
• Serum folate — always requested alongside B12 given their metabolic interdependence in the methylation cycle
• Homocysteine — sensitive functional marker elevated before serum B12 falls below reference range; reflects adequacy of both B12 and folate
• Methylmalonic acid (MMA) — highly specific for functional adenosylcobalamin deficiency; the most sensitive early marker of tissue-level B12 depletion; normal MMA with low-normal serum B12 substantially reduces the likelihood of functional deficiency

Private testing for MMA and homocysteine is available through major pathology providers across Australia at out-of-pocket cost when Medicare criteria are not met. For individuals on a vegan diet or with risk factors for deficiency, annual serum B12 monitoring with periodic MMA and homocysteine assessment provides a complete functional picture that serum B12 alone cannot.

Practical Recommendations

1. Default form preference: Methylcobalamin or hydroxocobalamin over cyanocobalamin for most individuals — active forms offer no disadvantage and potential advantages for those with suboptimal conversion capacity
2. Target 400–900 pmol/L serum B12, not merely "above the laboratory reference range lower limit"
3. Vegans: Begin supplementation immediately on dietary transition; 250 µg daily or 2,000 µg weekly; retest at 3 months initially to confirm adequacy of the chosen dose and form
4. MTHFR carriers: Methylcobalamin combined with 5-MTHF; avoid cyanocobalamin where possible
5. Fatigue or neurological symptoms with low-normal B12: Request MMA and homocysteine before concluding levels are adequate
6. Confirmed pernicious anaemia: Intramuscular hydroxocobalamin or high-dose oral supplementation (1,000 µg daily) with regular monitoring
7. Sublingual preparations: A reasonable practical choice; select methylcobalamin or adenosylcobalamin forms for neurological or fatigue applications

Vitamin B12 deficiency is preventable and correctable — but only if the appropriate form is chosen for the individual's metabolic context, the dose is sufficient for their absorption route, and monitoring targets functional sufficiency rather than the narrow binary of "deficient vs not deficient."